Arcturus Therapeutics Holdings Inc. filings document the regulatory record for a Nasdaq-listed commercial mRNA medicines and vaccines company with common stock registered under the symbol ARCT. Its Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations, and clinical or product disclosures tied to programs such as LUNAR-CF and KOSTAIVE.
The company’s proxy materials describe annual meeting matters, director elections, executive compensation, governance practices, and stockholder voting procedures. Other filings cover officer and board changes, registered security details, reporting-status notices such as Form 12b-25 notifications, and risk, capital-structure, collaboration, and development-stage disclosure relevant to its RNA therapeutics and vaccine business.
Arcturus Therapeutics Holdings Inc. (ARCT) common stock is the subject of an amended ownership report listing 1,678,069 shares, or 5.90% of the class, on each reporting-person cover page. Federated Hermes, Inc. and Voting Shares Irrevocable Trust each report sole voting and dispositive power over 1,678,069 shares. Thomas R. Donahue and Ann C. Donahue, as trustees of the trust, and J. Christopher Donahue, as president of Federated Hermes and a trustee, each report shared voting and dispositive power over 1,678,069 shares. The reporting persons disclaim beneficial ownership of securities held by the Managed Funds.
Arcturus Therapeutics Holdings Inc. (ARCT) reported interim results from its ongoing Phase 2 ARCT-810 study in OTC deficiency: treatment was generally safe and well tolerated, first morning fasting ammonia was reduced and/or maintained within the normal range, and glutamine was reduced. Participants at the 0.5 mg/kg dose level achieved mean glutamine values within the normal range; weight gain was observed in all participants.
LUNAR 2.0 showed a 40-fold improvement over LUNAR 1.0 in hEPO expression in one non-human-primate study and 38-fold greater potency than ATX-95 in hOTC expression in a separate study. Arcturus plans to initiate ARCT-2601 dosing near year-end in participants aged 12 years and older under an amended protocol integrating it into the current Phase 2 study, following favorable FDA feedback and regulatory-path clarity after a June Type C meeting.
Arcturus entered a definitive agreement to acquire AI discovery company myNEO, subject to customary closing conditions; closing is expected in October. Arcturus said the acquisition is intended to support mRNA design quality and target identification.
Arcturus Therapeutics Holdings Inc. (ARCT) reports that on August 25, 2026 it will present a scientific poster titled “Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with Ornithine Transcarbamylase Deficiency” at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism in Helsinki, Finland. The company states that additional data and the regulatory plan for the ARCT-810 program are expected to be communicated later this quarter. The ARCT-810 presentation is provided as Exhibit 99.1 and is described as furnished, not deemed filed or incorporated by reference into other securities law reports.
Arcturus Therapeutics Holdings Inc. reported Q2 2026 results with total revenue of $3.0 million, down from $28.3 million a year earlier, mainly reflecting reduced collaboration revenue as it moves toward terminating the CSL Seqirus agreement and regaining rights to KOSTAIVE and its infectious disease vaccine portfolio.
The company recorded a net loss of $23.8 million, or $0.84 per share, compared with a $9.2 million loss and $0.34 per share in Q2 2025. Cash and cash equivalents were $191.5 million as of June 30, 2026, versus $230.9 million at December 31, 2025, and management cites a cash runway of over two and a half years through year end 2028.
R&D expenses declined to $17.5 million from $29.6 million as spending was focused on highest-priority programs. ARCT-032 cystic fibrosis Phase 2 enrollment remains on schedule with a Phase 3 proceed decision expected in Q4 2026, while ARCT-810 Phase 2 enrollment and dosing have completed, with data and a regulatory plan to be communicated in Q3 2026.
Arcturus Therapeutics Holdings Inc. entered a strategic collaboration with Thermo Fisher Scientific to support the development of ARCT-032, its investigational mRNA therapy for cystic fibrosis. The relationship is governed by a Master Services Agreement and a detailed Project Addendum.
Under the Master Services Agreement, Thermo Fisher will contribute up to $40 million of clinical manufacturing services for ARCT-032, and Arcturus will engage Thermo Fisher’s PPD business for up to $40 million in contract research organization services. If ARCT-032 receives regulatory approval, Thermo Fisher would gain exclusive commercial manufacturing rights for a specified period, to be finalized in a separate supply agreement.
The initial term of the Master Services Agreement is five years, with automatic one-year renewals unless either party gives at least 90 days’ notice. The Project Agreement covers key activities such as technical transfer, engineering and clinical batches, fill-finish, product release, and stability studies, supporting ARCT-032 through late-stage clinical development and potential commercialization.
Arcturus Therapeutics Holdings Inc. director Edward W. Holmes received a grant of stock options as part of his 2026 annual board compensation. The award covers 15,000 options to buy common stock at an exercise price of $7.30 per share, expiring on June 5, 2036.
According to the footnote, the options vest monthly over one year from the grant date, meaning portions become exercisable each month during that period. This is a compensation-related grant, not an open-market purchase, and leaves Holmes with 15,000 derivative securities reported after the transaction.
Arcturus Therapeutics Holdings Inc. director Peter C. Farrell reported receiving a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $7.3000 per share and expire on June 5, 2036.
The filing describes this as the 2026 annual grant for his service on the Board of Directors. According to the footnote, the shares underlying the option vest monthly over a one-year period from the grant date. After this grant, Farrell holds options for 15,000 shares directly.
Arcturus Therapeutics Holdings Inc. reported that director James F. Barlow received a grant of stock options as part of his 2026 board compensation. The award covers 15,000 options to buy common stock at an exercise price of $7.30 per share.
According to the disclosure, the options vest monthly over a one-year period from the grant date, aligning the director’s compensation with the company’s performance over time. All 15,000 options are shown as held directly following this grant, with an expiration date in 2036.
Arcturus Therapeutics Holdings Inc. director John Markels received a grant of stock options as part of his 2026 annual board compensation. The award covers options to buy 15,000 shares of common stock at an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year from the grant date, and following this grant he holds stock options for 15,000 shares directly.